BLU.TO
Price:
$19.48
Market Cap:
$1.78B
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.[Read more]
Industry
Biotechnology
IPO Date
2000-06-22
Stock Exchange
TSX
Ticker
BLU.TO
According to BELLUS Health Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 33.42. This represents a change of 57.36% compared to the average of 21.24 of the last 4 quarters.
The mean historical Current Ratio of BELLUS Health Inc. over the last ten years is 11.73. The current 33.42 Current Ratio has changed 28.40% with respect to the historical average. Over the past ten years (40 quarters), BLU.TO's Current Ratio was at its highest in in the March 2023 quarter at 33.42. The Current Ratio was at its lowest in in the March 2017 quarter at 0.
Average
11.73
Median
12.09
Minimum
2.87
Maximum
22.42
Discovering the peaks and valleys of BELLUS Health Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 138.28%
Maximum Annual Current Ratio = 22.42
Minimum Annual Increase = -33.89%
Minimum Annual Current Ratio = 2.87
Year | Current Ratio | Change |
---|---|---|
2022 | 22.42 | 47.15% |
2021 | 15.23 | -15.86% |
2020 | 18.11 | 46.23% |
2019 | 12.38 | -33.89% |
2018 | 18.73 | 58.76% |
2017 | 11.80 | 72.36% |
2016 | 6.84 | 138.28% |
2015 | 2.87 | -22.37% |
2014 | 3.70 | -28.91% |
2013 | 5.20 | -29.07% |
The current Current Ratio of BELLUS Health Inc. (BLU.TO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
18.59
5-year avg
17.37
10-year avg
11.73
BELLUS Health Inc.’s Current Ratio is greater than Aptose Biosciences Inc. (0.80), greater than Oncolytics Biotech Inc. (4.99), greater than Theratechnologies Inc. (1.08), greater than Knight Therapeutics Inc. (3.41), greater than IMV Inc. (2.93),
Company | Current Ratio | Market cap |
---|---|---|
0.80 | $9.96M | |
4.99 | $123.18M | |
1.08 | $77.25M | |
3.41 | $570.51M | |
2.93 | $13.12M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BELLUS Health Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BELLUS Health Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is BELLUS Health Inc.'s Current Ratio?
How is the Current Ratio calculated for BELLUS Health Inc. (BLU.TO)?
What is the highest Current Ratio for BELLUS Health Inc. (BLU.TO)?
What is the 3-year average Current Ratio for BELLUS Health Inc. (BLU.TO)?
What is the 5-year average Current Ratio for BELLUS Health Inc. (BLU.TO)?
How does the current Current Ratio for BELLUS Health Inc. (BLU.TO) compare to its historical average?